CRIDANIMOD SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H10NO3.Na
Molecular Weight	275.2346
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[O-]C(=O)CN1C2=C(C=CC=C2)C(=O)C3=C1C=CC=C3

InChI

InChIKey=FQMLTEAEJZVTAJ-UHFFFAOYSA-M

InChI=1S/C15H11NO3.Na/c17-14(18)9-16-12-7-3-1-5-10(12)15(19)11-6-2-4-8-13(11)16;/h1-8H,9H2,(H,17,18);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C15H10NO3
Molecular Weight	252.2448
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02064725 | https://clinicaltrials.gov/ct2/show/NCT03077698

Cridanimod (Virexxa) is a small-molecule immunomodulator and interferon inducer, which, in preliminary studies, has been shown to increase progesterone receptor expression in endometrial tissue. Restoration of progesterone receptor expression may re-sensitize endometrial tumor tissue to progestin therapy in previously unresponsive tumors. Cridanimod was originally developed by Polysan and Pharmsynthez and licensed to Xenetic Biosciences. Virexxa is currently being studied in an ongoing Phase 2 multi-national study in conjunction with progestin therapy for the treatment of endometrial cancer in women with the recurrent or persistent disease who have failed progestin monotherapy.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
progesterone receptor signaling pathway 2 Target ID: GO:0050847 Sources: https://www.xeneticbio.com/news-media/press-releases/detail/38/xenetic-biosciences-announces-fda-acceptance-of	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Recurrent or persistent endometrial carcinoma 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02064725	Primary		Phase II 1132	Unknown Approved Use Unknown
Endometrial cancer 43 Sources: https://clinicaltrials.gov/ct2/show/NCT03077698	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
HIV-1 neutralization and tumor cell proliferation inhibition in vitro by simplified analogues of pyrido[4,3,2-mn]thiazolo[5,4-b]acridine marine alkaloids.	1992 Jul 24	1495008
[Increase in NK-activity using superlow doses of the immunomodulator cycloferon].	2001	11552653
Correlations between in vitro effects of preparations of interferon and its inducers on blood cells in patients with multiple sclerosis.	2001 Apr	11550032
[Effect of interferon inductors on infection induced by hepatitis C virus and activity of mRNA cytokines in cell cultures SW-13 and MT-4].	2002 Nov-Dec	12508677
Direct antiviral effect of cycloferon (10-carboxymethyl-9-acridanone) against adenovirus type 6 in vitro.	2003 Apr	12742573
[Use of cycloferon in a combined treatment of chlamydial conjunctivitis].	2003 Jan-Feb	12608044
[Neuroimmunopathologic aspects of epilepsy].	2004	15455693
[The preclinical diagnosis, prevention and treatment of postoperative iridocyclitis in patients after intraocular aphakia correction].	2004 Jul-Aug	15384841
[Cycloferon--a new domestic preparation for the prophylaxis of influenza and other acute respiratory viral infections].	2004 Nov-Dec	15636140
[Cyclopheron pretreatment in opisthorchiasis management in patients with viral hepatitis C].	2005	16404860
[Influence of cycloferon on the biological properties of bacterial intracellular pathogens].	2005 May-Jun	16028504
Structural, spectroscopic, and magnetic study of bis(9,10-dihydro-9-oxo-10-acridineacetate)bis(imidazole)bis(methanol) nickel(II).	2006 Dec 25	17173403
[Effect of intranasal aerosol-therapy with cycloferon on the function of respiration in patients with some forms of rhinitis].	2007 Jan	17327631
[Cycloferon in the treatment of infectious diseases].	2008	18942425
[Immunomodulators in the "gold standard" of the chronic viral hepatitis C therapy].	2008	18942421
[Improvement of natural resistance in children for prophylaxis of influenza and acute respiratory tract viral infections (results of multicenter randomized trials)].	2009	20415263
[Up-to-date approach to treatment of inflammatory infections in the maxillofacial region].	2009	19711852
[Cycloferon efficacy in viral and bacterial diseases of children (clinical review)].	2010	21574424
[Optimization of prophylaxis of relapses of primary erysipelas with the use of cyclopheron].	2010	21395032
[Use of cycloferon in the treatment of patients with pulmonary tuberculosis with mild clinical manifestations].	2010	21381350
[Efficiency of using cycloferon as part of combined therapy for chronic hepatitis C (a review of multicenter clinical trials)].	2010	21341470
[The cytokine profile in the acute period of tick-borne neuroinfections in children].	2010	21322819
[Clinical laboratory approaches to parodontitis treatment optimization].	2010	21311440
[Effectiveness of cycloferon liniment in a complex treatment, and monitoring of cytokine profile of gingival fluid of patients with paradontitis].	2010	21207889
[Optimization of parodontitis treatment of patients with tuberculosis].	2010	21186645
[Changes of functional activity of peripheral blood leukocytes during the immunotherapy of tick-borne infections in children].	2010	21183923
[Cycloferon in complex therapy of chronic brucellosis].	2010	21140564
[The use of cycloferon in the combined treatment of tuberculosis patients infected with HIV and viral hepatitis].	2010	21089459
[Correction of immunity disorders, treatment of intestinal infections and disbiosis in children (clinical review)].	2010	21033474
[Pathogenetically substantiated therapy of patients with virus hepatitis C, quality of life, and the disease outcome risk (clinical survey)].	2010	20695208
[Efficacy of cycloferon in the treatment of brucellosis].	2010	20608067
[Use of immunomodulators in the therapy of chronic hepatitis C: improving standard approach].	2010 Apr	20486553
[Combined cycloferon treatment of tuberculosis in patients infected with HIV].	2010 Jul	20821978
[Focal immunophysiotherapy in combined treatment of men with manifestations of papilloma virus infection].	2010 Nov-Dec	21427998

Patents

Sample Use Guides

In Vivo Use Guide

Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).

Route of Administration: Intramuscular

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:48:47 GMT 2023` Edited by `admin` on `Fri Dec 15 17:48:47 GMT 2023`
Record UNII	54W868ROLR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CRIDANIMOD SODIUM

Common Name

English

Cridanimod sodium [WHO-DD]

Common Name

English

NEOVIR

Brand Name

English

SODIUM 9-OXO-10-ACRIDINEACETATE

Systematic Name

English

XBIO-101

Code

English

CAMEDONE

Common Name

English

10(9H)-ACRIDINEACETIC ACID, 9-OXO-, SODIUM SALT (1:1)

Common Name

English

CAMEDON

Common Name

English

Camedon [WHO-DD]

Common Name

English

Camedon sodium [WHO-DD]

Common Name

English

N-(CARBOXYMETHYL)-9-ACRIDONE SODIUM SALT

Common Name

English

Classification Tree Code System Code

FDA ORPHAN DRUG

267508